NCT05681728

A Phase II Study Evaluating the Efficacy and Safety of Pembrolizumab in Combination With Chemotherapy as Neoadjuvant Therapy for Triple-negative Breast Cancer

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 26 (estimated)
• Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

A Phase II study that evaluating the efficacy and safety of pembrolizumab in combination with chemotherapy as neoadjuvant therapy for triple-negative breast cancer in the Chinese population

Conditions

• Breast Cancer

Interventions

Type	Name	Description
DRUG	Pembrolizumab	On Day 1 of each cycle in the neoadjuvant and adjuvant phases of the study for a total of 17 cycles; intravenous (IV) infusion
DRUG	Paclitaxel	On Day 1 of Cycles 1-4 in the neoadjuvant phase of the study; IV infusion
DRUG	Epirubicin	On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV injection
DRUG	Cyclophosphamide	On Day 1 of Cycles 5-8 of the neoadjuvant phase of the study; IV infusion

Timeline

• Start date: 2022-02-01
• Primary completion: 2024-02-01
• Completion: 2024-06-01
• First posted: 2023-01-12
• Last updated: 2023-01-12

Locations

1 site across 1 country: China